Status:
COMPLETED
A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.
Lead Sponsor:
Pfizer
Conditions:
Asthma
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
A study to determine the ability of different doses of PF-610,355 to open the airways in asthmatic patients by comparison with placebo and a marketed drug that also opens the airways in asthmatic pati...
Eligibility Criteria
Inclusion
- Reversible asthmatic patients (\>15% increase in FEV1 following 200ug salbutamol).
- FEV1 greater than or equal to 60% predicted
- Stable disease for at least the previous 3 months
Exclusion
- Subjects requiring rescue medication on greater than 2 occasions in the 72 hours prior to screening
- Subjects with a history of pulmonary disease other than asthma.
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00468975
Start Date
May 1 2007
Last Update
November 1 2010
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Berlin, Germany, 14050
2
Pfizer Investigational Site
Großhansdorf, Germany, 22927
3
Pfizer Investigational Site
Wiesbaden, Germany, 65187
4
Pfizer Investigational Site
Gothenburg, Sweden, 413 45